Genmab A/S Dkk (GNMSF) 41.7500 $GNMSF Genmab Reaches $22

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Genmab A/S Dkk (GNMSF) 41.7500 $GNMSF

Genmab Reaches $22 Million Milestone in Daratumumab Collaboration with Janssen
GlobeNewswire - Wed Mar 26, 5:58PM CDT
Company Announcement

Genmab Announces Phase III Study of Daratumumab in Relapsed or Refractory Multiple Myeloma
GlobeNewswire - Tue Mar 04, 11:48PM CST
Company Announcement

Genmab 2013 Annual Report
GlobeNewswire - Tue Mar 04, 10:23AM CST
Genmab A/S (Copenhagen:GEN) today published its Annual Report for 2013. Below is a summary from the report of business progress and financial performance for the year, and financial outlook for 2014. The full report is attached as a PDF file and can be found on the investor section of the company's website, www.genmab.com.

Arzerra(R) Fourth Quarter and Full Year 2013 Net Sales Figures
GlobeNewswire - Wed Feb 05, 6:15AM CST
Company Announcement

Major Shareholder Announcement
GlobeNewswire - Wed Jan 29, 12:57PM CST
Company Announcement

Can Genmab (GNMSF) Run Higher on Strong Earnings Estimate Revisions? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jan 02, 7:47AM CST
Genmab could be an interesting play for investors because, not only does the stock have decent short-term momentum, but it is seeing solid activity on the earnings estimate revision front as well.

Why Genmab A/S (GNMSF) Stock Might be a Great Pick - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Dec 31, 7:58AM CST
Genmab performance and growth prospects can be a good choice for the investors.

GSK and Genmab Receive Priority Review from FDA for Arzerra(r) (ofatumumab) as 1st Line Treatment for Chronic Lymphocytic Leukemia (CLL)
GlobeNewswire - Tue Dec 17, 3:00PM CST
Company Announcement

Genmab to Receive Milestone Payment in DuoBody Platform Collaboration with Janssen - Financial Guidance Improved
GlobeNewswire - Fri Dec 06, 9:23AM CST
Company Announcement

Genmab Reaches Fourth Milestone in Lundbeck Collaboration
GlobeNewswire - Fri Dec 06, 6:45AM CST
Company Announcement

Genmab Reaches First Milestone in Daratumumab Collaboration With Janssen & Improves 2013 Financial Guidance
GlobeNewswire - Tue Nov 26, 1:08AM CST
Company Announcement

Capital Increase in Genmab as a Result of Employee Warrant Exercise and Projection of Improved Cash Position at the End of 2013
GlobeNewswire - Wed Nov 13, 11:54AM CST
Company Announcement

Genmab Announces Financial Results for the First Nine Months of 2013
GlobeNewswire - Wed Nov 06, 10:17AM CST
-- Applications to expand Arzerra(r) (ofatumumab) label submitted in US & EU

Waldenstrom Macroglobulinemia - Pipeline Review, H2 2013
M2 - Wed Nov 06, 2:49AM CST
Research and Markets (http://www.researchandmarkets.com/research/xp8wxq/waldenstrom) has announced the addition of the "Waldenstrom Macroglobulinemia - Pipeline Review, H2 2013" report to their offering. 'Waldenstrom Macroglobulinemia - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Waldenstrom Macroglobulinemia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Waldenstrom Macroglobulinemia. Scope - A snapshot of the global therapeutic scenario for Waldenstrom Macroglobulinemia. - A review of the Waldenstrom Macroglobulinemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Waldenstrom Macroglobulinemia pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Gilead Sciences, Inc. Millennium Pharmaceuticals, Inc. Genmab A/S Celgene Corporation Onyx Pharmaceuticals, Inc. Accentia Biopharmaceuticals, Inc. Pharmacyclics, Inc. For more information visit http://www.researchandmarkets.com/research/xp...aldenstrom About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Arzerra(r) Third Quarter 2013 Net Sales Figures
GlobeNewswire - Wed Oct 23, 6:09AM CDT
Company Announcement

Genmab Announces Positive Top-Line Phase II Results of Ofatumumab in Multiple Sclerosis
GlobeNewswire - Thu Oct 10, 1:18PM CDT
Company Announcement

FDA Grants GSK and Genmab's Arzerra(R) (Ofatumumab) Breakthrough Therapy Designation for Previously Untreated Chronic Lymphocytic Leukemia
GlobeNewswire - Fri Sep 13, 3:36PM CDT
Company Announcement

Update on J&J/Genmab's Daratumumab - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Sep 12, 11:10AM CDT
Patient recruitment is expected to start shortly.

Cervical Cancer - Pipeline Review, H2 2013
M2 - Thu Sep 12, 8:54AM CDT
Research and Markets (http://www.researchandmarkets.com/research/lpg7wz/cervical_cancer) has announced the addition of the "Cervical Cancer - Pipeline Review, H2 2013" report to their offering. 'Cervical Cancer - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Cervical Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Cervical Cancer. Scope - A snapshot of the global therapeutic scenario for Cervical Cancer. - A review of the Cervical Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Cervical Cancer pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned F. Hoffmann-La Roche Ltd. Helix BioPharma Corp. Sanofi-Aventis GlaxoSmithKline plc Gilead Sciences, Inc. Daiichi Sankyo Company, Ltd Amorfix Life Sciences Ltd. MediGene AG Nanotherapeutics, Inc. Novartis AG Chong Kun Dang Pharmaceutical Taiho Pharmaceutical Co., Ltd. Zeria Pharmaceutical Co Ltd Genmab A/S CEL-SCI Corporation Advaxis, Inc. 3SBio Inc. Dendreon Corporation Transgene SA Antigen Express, Inc. Shantha Biotechnics Limited and many more... For more information visit http://www.researchandmarkets.com/research/lp...cal_cancer About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

NVE Revenue Pull-Forward Raises Hard Investor Questions

Updated Category News Views 110

A Quarter Can Look Great Until It Doesn’t NVE investors got a nasty lesson in revenue timing, the sort that makes even old hands check the fine print twice. On July 22, 2026, the company reported sequential revenue growth of 43% and net-income growth of 23%. The next trading day, shares vaulted $47.53, or 54%. Then came October, and the floor gave way: NVE reported that...

Continue Reading
Holland America Puts 2028 Alaska Demand on Display

Updated Category News Views 123

Alaska’s interior is where a cruise brochure either earns its keep or gets exposed. Holland America Line is opening bookings for 2028 Alaska Cruisetours nearly two years ahead, tying a coast-and-land product to the reimagined Oosterdam’s Alaska debut. That is not merely another itinerary release. It is a fairly deliberate attempt to sell a bigger, longer and...

Continue Reading
NYSE Message Record Puts Market Plumbing Into Focus

Updated Category News Views 120

A trillion messages is not a cute little exchange statistic; it is the sort of number that tells you whether the market’s pipes can keep working when everybody starts shouting at once. NYSE says it handled a record 1.166 trillion messages in one day on November 5, roughly 4% above the prior high set amid April 2025 volatility. Better yet, according to the exchange,...

Continue Reading
Yiwu Squishies Turn Viral Demand Into Factory Backlogs Worldwide

Updated Category News Views 87

A pizza-shaped stress toy booking more than one million units is the sort of detail that makes a jaded market watcher sit up before rolling his eyes at the word “viral.” Yiwu’s squishy-toy surge appears to have moved beyond a few social-media impulses and into actual factory scheduling, repeat purchase orders and supermarket procurement. That is meaningful. It is...

Continue Reading
Five Films Put Modern Infrastructure Under a Lens

Updated Category News Views 121

Most infrastructure only earns a thought when it breaks, and that is precisely the nerve these films are trying to touch. Nicely Done Productions has released the final five installments of its ten-part Threads of Connectivity documentary series, hosted on National Geographic's global digital platform. The subjects are illycaffè, Cargill, Honeywell Aerospace, Western...

Continue Reading
Africa’s Digital Leap Still Has a 64% Usage Problem

Updated Category News Views 100

A continent can be blanketed in signal and still feel digitally stranded. That is the stubborn fact sitting inside the GSMA Digital Africa Index 2026: mobile broadband reaches 92% of Africa’s population, while only 28% use mobile internet on their own devices. The 64% usage gap is not a rounding error or a tidy policy footnote. It is the whole unfinished job. From an...

Continue Reading
MFB Bancorp Offering Puts Chicago Bank Conversion First

Updated Category News Views 70

A small Chicago thrift is asking investors to fund a corporate makeover, and the fine print matters more than the $10 sticker price. MFB Bancorp has commenced an offering tied to the planned conversion of Mutual Federal Bancorp, MHC from a mutual holding company structure into a stock holding company. This is not some high-growth bank story with a shiny new branch map. It...

Continue Reading
StoneX Selloff Puts Earnings Quality Under a Harsh Lens

Updated Category News Views 111

A revenue beat can turn downright useless when the profit line springs a leak. StoneX Group delivered operating revenue above expectations and record full-year results, then watched investors hammer the stock after fiscal fourth-quarter diluted earnings per share landed at $0.66. That was $0.15 below the roughly $0.81 consensus cited in the notice, and other estimates...

Continue Reading
IDEMIA Lands Sweden's Critical 5G Connectivity Job

Updated Category News Views 108

A hospital monitor going dark because a device was misprovisioned is not the kind of connectivity hiccup anybody gets to shrug off. That is why IDEMIA Secure Transactions winning the Region Västra Götaland assignment deserves more attention than the usual telecom plumbing announcement. The region is building what it calls Sweden's largest private 5G network, and the job...

Continue Reading
Securitize Tests the IPO Clock With Anthropic Tokens

Updated Category News Views 93

Anthropic did not even get a full trading day to itself before the tokenization crowd arrived. Securitize says Anthropic stock became available through Securitize Stocks on Solana on the company’s first day as a public company, a loud little signal that the old IPO playbook is being prodded from the edges. For investors, this is not merely another crypto-flavored...

Continue Reading

Top 5 Most Recently Viewed Articles

Exploring the Growth of the Global Gifts Retailing Market

Updated Category News Views 120

The Gifts Retailing Market is Evolving Rapidly The global gifts retailing industry is projected to experience substantial growth, with estimates indicating an increase of USD 11.01 billion from 2024 to 2028. Several influential factors are driving this trend, notably the rising demand for seasonal decorations and a stronger gifting culture. As consumers increasingly...

Continue Reading
Exploring the Risks Behind the Monumental Rise of Big Tech

Updated Category News Views 163

Understanding the Current Landscape of Big Tech Investment In recent discussions about the tech industry, significant concerns have bubbled to the surface regarding the sustainability of current market valuations. Analysts have pointed out that the optimism surrounding the surge in equity prices may be fueled by unrealistic expectations. John Hussman notably remarked on...

Continue Reading
Senator Markwayne Mullin Makes Notable Stock Purchase in LPL

Updated Category News Views 246

Senator Markwayne Mullin's Recent Stock Transactions Recent financial disclosures reveal that Senator Markwayne Mullin has made a significant investment in LPL Financial Holdings Inc (NASDAQ: LPLA). The purchase, valued between $233,016 and $670,000, was filed recently and adds to his active trading portfolio. This transaction indicates Mullin's ongoing interest in the...

Continue Reading
Pathward Financial: Sale of Insurance Business Extended

Updated Category News Views 123

Pathward Financial, Inc. (NASDAQ: CASH), known as Meta Financial Group in the past, extended the closing of its commercial insurance premium finance business sale to October 22, from an initial deadline of October 1. Traders were quick to sniff out that this delay wasn’t just a minor hiccup—it pointed to deeper operational challenges. Delays and What They Mean for...

Continue Reading
Vallourec's Major Supply Order from ADNOC Signals Growth

Updated Category News Views 198

Vallourec's Major Supply Agreement with ADNOC Vallourec, a global leader in premium seamless tubular solutions, has successfully secured a significant order from the Abu Dhabi National Oil Company (ADNOC). This order includes supplying over 30,000 tons of carbon steel tubulars and related accessories, prominently featuring VAM premium connections. This transaction forms...

Continue Reading